A massive announcement came from Asep (CSE: ASEP) last week. The company has announced that its novel anti-biofilm peptide technology is in advanced development through its collaboration with its pre-clinical partner, iFyber, with grant funding from the US Army.
The Company's ongoing collaboration with iFyber is focused on developing wound dressings that incorporate Asep’s novel peptide technology. Beyond preventing and treating bacterial biofilm infections, the dressings are expected to promote wound healing, which is essential when treating injuries in the field.
Beyond this military application, there were 8.4 million purulent skin and soft tissue infections in the USA in 2015. Staggeringly, there is not a single FDA-approved treatment for biofilm infections. $ASEP.C is addressing this medical shortcoming head-on. Representing a massive opportunity for $ASEP.C and its partner company.
$ASEP.C share prices haven’t yet seen the staggering movement you would expect from this announcement. Although, they have bounced a considerable 31% from all-time lows since this news was announced. $.43 will be a key resistance zone to watch as shares of $ASEP.C attempt to establish a bullish trend.
$ASEP.C is currently trading at $.345 and the company is valued at an MCAP of $19.36 million.
https://ceo.ca/@newswire/asep-medical-inc-announces-its-antibiofilmanti-inflammatory